262 related articles for article (PubMed ID: 16075823)
1. Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease.
Levy DR; Pearson TA
Clin Cardiol; 2005 Jul; 28(7):317-20. PubMed ID: 16075823
[TBL] [Abstract][Full Text] [Related]
2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
3. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
[TBL] [Abstract][Full Text] [Related]
4. The facts behind niacin.
Hochholzer W; Berg DD; Giugliano RP
Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):227-40. PubMed ID: 21893559
[TBL] [Abstract][Full Text] [Related]
5. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Ahmed MH
J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
[TBL] [Abstract][Full Text] [Related]
6. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
Chrysant SG; Ibrahim M
J Clin Hypertens (Greenwich); 2006 Jul; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
[TBL] [Abstract][Full Text] [Related]
7. Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention.
Chapman MJ
Cardiovasc Drugs Ther; 2005 Mar; 19(2):135-9. PubMed ID: 16025232
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
9. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials.
Michos ED; Sibley CT; Baer JT; Blaha MJ; Blumenthal RS
J Am Coll Cardiol; 2012 Jun; 59(23):2058-64. PubMed ID: 22520249
[TBL] [Abstract][Full Text] [Related]
10. Do patients on statins also need niacin?
Jones KW
JAAPA; 2013 Jul; 26(7):9-10. PubMed ID: 23923280
[TBL] [Abstract][Full Text] [Related]
11. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
12. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
Wong ND; Chuang J; Zhao Y; Rosenblit PD
J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
[TBL] [Abstract][Full Text] [Related]
13. Fibrates and niacin: is there a place for them in clinical practice?
Wierzbicki AS; Viljoen A
Expert Opin Pharmacother; 2014 Dec; 15(18):2673-80. PubMed ID: 25318657
[TBL] [Abstract][Full Text] [Related]
14. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
15. Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol.
Toth PP; Zarotsky V; Sullivan JM; Laitinen D
Curr Med Res Opin; 2009 Jun; 25(6):1355-63. PubMed ID: 19425901
[TBL] [Abstract][Full Text] [Related]
16. Benefit on atherosclerosis of adding niacin in patients with low HDL-cholesterol taking a statin.
Amsterdam EA
Prev Cardiol; 2005; 8(2):130. PubMed ID: 15860992
[No Abstract] [Full Text] [Related]
17. Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.
Sharma RK; Singh VN; Reddy HK
Vasc Health Risk Manag; 2009; 5():793-9. PubMed ID: 19812691
[TBL] [Abstract][Full Text] [Related]
18. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events.
Taher TH; Dzavik V; Reteff EM; Pearson GJ; Woloschuk BL; Francis GA
Am J Cardiol; 2002 Feb; 89(4):390-4. PubMed ID: 11835917
[TBL] [Abstract][Full Text] [Related]
20. Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy.
Airan-Javia SL; Wolf RL; Wolfe ML; Tadesse M; Mohler E; Reilly MP
Am Heart J; 2009 Apr; 157(4):687.e1-8. PubMed ID: 19332196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
